ArticleJournal of hepatocellular carcinoma2018

Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma.

Lynn G Feun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.